Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/77182
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKanokwan Pinyopornpanishen_US
dc.contributor.authorApinya Leerapunen_US
dc.contributor.authorKanokporn Pinyopornpanishen_US
dc.contributor.authorNipon Chattipakornen_US
dc.date.accessioned2022-10-16T07:24:28Z-
dc.date.available2022-10-16T07:24:28Z-
dc.date.issued2021-01-01en_US
dc.identifier.issn20051212en_US
dc.identifier.issn19762283en_US
dc.identifier.other2-s2.0-85119363915en_US
dc.identifier.other10.5009/gnl20367en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85119363915&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/77182-
dc.description.abstractNonalcoholic fatty liver disease (NAFLD) patients with diabetes constitute a subgroup of patients with a high rate of liver-related complications. Currently, there are no specific drug recommendations for these patients. Metformin, a conventional insulin sensitizer agent, has been widely prescribed in patients with diabetes. Metformin treatment has been shown to be effective at alleviating hepatic lipogenesis in animal models of NAFLD, with a variety of mechanisms being deemed responsible. To date, most studies have enrolled diabetic patients who are treated with metformin, with the drug being taken continuously throughout the study. Although evidence exists regarding the benefits of metformin for NAFLD in preclinical studies, reports on the efficacy of metformin in adult NAFLD patients have had some discrepancies regarding changes in liver biochemistry and hepatic fat content. Evidence has also suggested possible effects of metformin as regards the prevention of hepatocellular carcinoma tumorigenesis. This review was performed to comprehensively summarize the available in vitro, in vivo and clinical studies regarding the effects of metformin on liver steatosis for the treatment of adult NAFLD patients with diabetes. Consistent reports as well as controversial findings are included in this review, and the mechanistic insights are also provided. In addition, this review focuses on the efficacy of metformin as a monotherapy and as a combined therapy with other antidiabetic medications.en_US
dc.subjectMedicineen_US
dc.titleEffects of metformin on hepatic steatosis in adults with nonalcoholic fatty liver disease and diabetes: Insights from the cellular to patient levelsen_US
dc.typeJournalen_US
article.title.sourcetitleGut and Liveren_US
article.volume15en_US
article.stream.affiliationsChiang Mai Universityen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.